{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:20:29Z","timestamp":1789154429246,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,7]]},"DOI":"10.7759\/cureus.78665","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:34:31Z","timestamp":1738928071000},"source":"Crossref","is-referenced-by-count":1,"title":["High-Risk Nonsecretory Multiple Myeloma With Poor Response to Daratumumab-Based Chemotherapy"],"prefix":"10.7759","author":[{"given":"Surendra","family":"Khanal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameela","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle RA","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003, 78:21-33. 10.4065\/78.1.21","journal-title":"Mayo Clin Proc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan AJ","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al.. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018, 4:1221-7. 10.1001\/jamaoncol.2018.2128","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren O","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, et al.. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009, 113:5412-7. 10.1182\/blood-2008-12-194241","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle RA","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al.. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006, 354:1362-9. 10.1056\/NEJMoa054494","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong K","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, et al.. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016, 175:252-64. 10.1111\/bjh.14213","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03984-w","article-title":"Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma","volume":"99","author":"Migkou M","year":"2020","unstructured":"Migkou M, Avivi I, Gavriatopoulou M, et al.. Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Ann Hematol. 2020, 99:1251-5. 10.1007\/s00277-020-03984-w","journal-title":"Ann Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06561.x","article-title":"Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma","volume":"137","author":"Kyrtsonis MC","year":"2007","unstructured":"Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al.. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol. 2007, 137:240-3. 10.1111\/j.1365-2141.2007.06561.x","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review","volume":"162","author":"Regelink JC","year":"2013","unstructured":"Regelink JC, Minnema MC, Terpos E, et al.. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol. 2013, 162:50-61. 10.1111\/bjh.12346","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2436","article-title":"Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants","volume":"101","author":"Avet-Loiseau H","year":"2003","unstructured":"Avet-Loiseau H, Garand R, Lod\u00e9 L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003, 101:1570-1. 10.1182\/blood-2002-08-2436","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld P","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, et al.. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016, 127:2955-62. 10.1182\/blood-2016-01-631200","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12478","article-title":"Clinical course and prognosis of non-secretory multiple myeloma","volume":"95","author":"Chawla SS","year":"2015","unstructured":"Chawla SS, Kumar SK, Dispenzieri A, et al.. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol. 2015, 95:57-64. 10.1111\/ejh.12478","journal-title":"Eur J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri S","year":"2020","unstructured":"Giri S, Grimshaw A, Bal S, et al.. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA Oncol. 2020, 6:1759-65. 10.1001\/jamaoncol.2020.4338","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie BG","year":"2020","unstructured":"Durie BG, Hoering A, Sexton R, et al.. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020, 10:53. 10.1038\/s41408-020-0311-8","journal-title":"Blood Cancer J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass J","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, et al.. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019, 20:e302-12. 10.1016\/S1470-2045(19)30309-2","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198788","article-title":"The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma","volume":"114","author":"Chee CE","year":"2009","unstructured":"Chee CE, Kumar S, Larson DR, et al.. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 2009, 114:2617-8. 10.1182\/blood-2009-01-198788","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/252748-high-risk-nonsecretory-multiple-myeloma-with-poor-response-to-daratumumab-based-chemotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:34:32Z","timestamp":1738928072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/252748-high-risk-nonsecretory-multiple-myeloma-with-poor-response-to-daratumumab-based-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.78665","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}